- Imugene (IMU) shares are trading green today on news the healthcare stock was granted a core U.S. patent
- The patent protects Imugene’s B-Cell immunotherapy portfolio, which includes a range of cancer vaccines
- Specifically, the new patient protects the composition and use of the vaccines, which are licenced by Ohio State University
- Imugene’s CEO and Managing Director, Leslie Chong, said winning the key U.S. patent is a significant step for the company
- The patent is valid up until 2035
- Today, Imugene shares are up 3.92 per cent to trade for 5.3 cents each
Imugene: Receives key U.S. patent for cancer therapies
